GlobalData on MSN
WHO directs antibiotic development to priority pathogens
WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.
Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...
Pipeline of antibiotics under development is shrinking putting children at risk amid global drug resistance crisis, report ...
The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report. View on euronews ...
Imagine a future where common infections once easily cured by antibiotics become life-threatening again. This is the growing reality posed by antimicrobial resistance (AMR), now recognized as one of ...
Health and Me on MSN
WHO's new guidance to accelerate antibiotics development for 3 deadly bacterial infections
As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.
Race for new antibiotics intensifies as WHO warns drug pipeline remains thin, and remains structurally unfit to support antibiotic innovation ...
DUBUQUE, Iowa (KCRG) — Scorpion venom could be used to develop new antibiotics and may help address the growing problem of antibiotic resistance. University of Dubuque biology professor Dr. Adam ...
New research from DTU indicates that the outcome of a resistance measurement may depend on the conditions under which the bacterium is tested ...
Antibiotic susceptibility in resistant bacteria is not static. New research shows that bacteria harboring resistance genes may respond differently to antibiotics if they are tested under conditions ...
Scientists have created a genomic blueprint for Aeromonas bacteria, which can cause antibiotic-resistant diarrheal disease—with symptoms often misidentified as cholera—in humans and animals.
Report Highlights the Company's Collaboration with GARDP to Develop NUZOLVENCE (R) (zoliflodacin) for Oral Suspension for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results